115 related articles for article (PubMed ID: 22504780)
1. Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine.
Hidaka T; Fujimura T; Watabe A; Hashimoto A; Haga T; Onami K; Mizuashi M; Aiba S
Acta Derm Venereol; 2012 Nov; 92(6):654-5. PubMed ID: 22504780
[No Abstract] [Full Text] [Related]
2. Rapid tumor shrinkage with lapatinib plus capecitabine in a patient with massive liver involvement.
Giotta F; Latorre A; Cramarossa A; Simone G; Florio C; Oliva S; Lorusso V
Tumori; 2013; 99(6):278e-81e. PubMed ID: 24503803
[TBL] [Abstract][Full Text] [Related]
3. Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study.
Mohammed TA; Dennie T; Holen KD
Clin Adv Hematol Oncol; 2011 Jun; 9(6):492-500. PubMed ID: 21841751
[No Abstract] [Full Text] [Related]
4. Scalp angiosarcoma presented as skin-coloured papules.
Byun JY; Suhng EA; Cheong SH; Choi YW; Choi HY
Acta Derm Venereol; 2014 Jul; 94(4):461-2. PubMed ID: 24352247
[No Abstract] [Full Text] [Related]
5. Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent Lapatinib and Capecitabine.
Abboud M; Saghir NS; Salame J; Geara FB
Breast J; 2010; 16(6):644-6. PubMed ID: 21070441
[TBL] [Abstract][Full Text] [Related]
6. High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.
Rhee J; Han SW; Cha Y; Ham HS; Kim HP; Oh DY; Im SA; Park JW; Ro J; Lee KS; Park IH; Im YH; Bang YJ; Kim TY
Breast Cancer Res Treat; 2011 Jan; 125(1):107-14. PubMed ID: 20936340
[TBL] [Abstract][Full Text] [Related]
7. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
Ryan Q; Ibrahim A; Cohen MH; Johnson J; Ko CW; Sridhara R; Justice R; Pazdur R
Oncologist; 2008 Oct; 13(10):1114-9. PubMed ID: 18849320
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
Glück S; Castrellon A
Am J Ther; 2009; 16(6):585-90. PubMed ID: 19287304
[TBL] [Abstract][Full Text] [Related]
9. An Index Case of Cutaneous Hodgkin Lymphoma and Review of the Literature.
Huong G; Olson LC; Rippis GE; Magro CM
Am J Dermatopathol; 2016 Oct; 38(10):739-43. PubMed ID: 26959698
[TBL] [Abstract][Full Text] [Related]
10. Primary cutaneous CD4/CD8-/- TCRαβ T-cell lymphoma.
Fujimoto N; Kito K; Yoshida T; Tanaka T
Acta Derm Venereol; 2015 Jan; 95(1):106-7. PubMed ID: 24890876
[No Abstract] [Full Text] [Related]
11. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Cameron D; Casey M; Press M; Lindquist D; Pienkowski T; Romieu CG; Chan S; Jagiello-Gruszfeld A; Kaufman B; Crown J; Chan A; Campone M; Viens P; Davidson N; Gorbounova V; Raats JI; Skarlos D; Newstat B; Roychowdhury D; Paoletti P; Oliva C; Rubin S; Stein S; Geyer CE
Breast Cancer Res Treat; 2008 Dec; 112(3):533-43. PubMed ID: 18188694
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer.
Cameron D
Clin Adv Hematol Oncol; 2007 Jun; 5(6):456-8. PubMed ID: 17679920
[No Abstract] [Full Text] [Related]
14. A case of small-cell prostate cancer with a metastasis to the scalp.
Kraft Rovere R; Silva de Lima A; Casemiro KP
Jpn J Clin Oncol; 2013 Nov; 43(11):1156. PubMed ID: 24186938
[No Abstract] [Full Text] [Related]
15. Worrisome solitary dark growing nodule on the vertex: challenge. Atypical cellular blue nevus.
Borghi A; Minghetti S; Rinaldi R; Corazza M; Virgili A
Am J Dermatopathol; 2013 Feb; 35(1):92-3, 109. PubMed ID: 23353679
[No Abstract] [Full Text] [Related]
16. Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.
Montagna E; Cancello G; Torrisi R; Rizzo S; Scarano E; Colleoni M
Ann Oncol; 2010 Mar; 21(3):667-668. PubMed ID: 20032127
[No Abstract] [Full Text] [Related]
17. A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy.
Kefeli U; Bilici A; Ustaalioglu BB; Kefeli AU; Yildirim ME; Seker M; Gumus M
Arch Gynecol Obstet; 2011 Feb; 283(2):405-7. PubMed ID: 20495812
[No Abstract] [Full Text] [Related]
18. Lapatinib for the treatment of HER2-overexpressing breast cancer.
Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A
Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
Baselga J; Segalla JG; Roché H; Del Giglio A; Pinczowski H; Ciruelos EM; Filho SC; Gómez P; Van Eyll B; Bermejo B; Llombart A; Garicochea B; Durán MÁ; Hoff PM; Espié M; de Moraes AA; Ribeiro RA; Mathias C; Gil Gil M; Ojeda B; Morales J; Kwon Ro S; Li S; Costa F
J Clin Oncol; 2012 May; 30(13):1484-91. PubMed ID: 22412143
[TBL] [Abstract][Full Text] [Related]
20. Precursor B-cell lymphoblastic lymphoma with only cutaneous involvement.
Kawakami T; Kimura S; Kinoshita A; Kondo K; Soma Y
Acta Derm Venereol; 2009; 89(5):540-1. PubMed ID: 19734992
[No Abstract] [Full Text] [Related]
[Next] [New Search]
